Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
- PMID: 33741444
- DOI: 10.1016/j.annonc.2021.03.002
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
Conflict of interest statement
Disclosure Outside submitted work TES reports personal fees from Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, and Regeneron. Grant support for clinical trials (institution) outside the submitted work from Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, and Regeneron.
Comment on
-
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.Ann Oncol. 2021 May;32(5):620-630. doi: 10.1016/j.annonc.2021.02.012. Epub 2021 Feb 24. Ann Oncol. 2021. PMID: 33639216 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
